As of 2025-06-01, the EV/EBITDA ratio of Celon Pharma SA (CLN.WA) is 79.48. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CLN.WA's latest enterprise value is 1,181.35 mil PLN. CLN.WA's TTM EBITDA according to its financial statements is 14.86 mil PLN. Dividing these 2 quantities gives us the above CLN.WA EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 7.7x - 16.2x | 12.1x |
| Forward P/E multiples | 7.0x - 15.5x | 9.6x |
| Fair Price | 2.01 - 4.55 | 3.05 |
| Upside | -90.9% - -79.3% | -86.1% |
| Date | EV/EBITDA |
| 2025-05-29 | 79.48 |
| 2025-05-28 | 79.66 |
| 2025-05-27 | 82.20 |
| 2025-05-26 | 81.84 |
| 2025-05-23 | 82.02 |
| 2025-05-22 | 80.93 |
| 2025-05-21 | 85.46 |
| 2025-05-20 | 86.01 |
| 2025-05-19 | 86.01 |
| 2025-05-16 | 87.27 |
| 2025-05-15 | 86.55 |
| 2025-05-14 | 87.82 |
| 2025-05-13 | 89.27 |
| 2025-05-12 | 86.55 |
| 2025-05-09 | 84.92 |
| 2025-05-08 | 86.19 |
| 2025-05-07 | 87.09 |
| 2025-05-06 | 87.45 |
| 2025-05-05 | 88.00 |
| 2025-05-02 | 86.19 |
| 2025-04-30 | 93.07 |
| 2025-04-29 | 96.33 |
| 2025-04-28 | 93.98 |
| 2025-04-25 | 92.17 |
| 2025-04-24 | 92.89 |
| 2025-04-23 | 92.53 |
| 2025-04-22 | 91.44 |
| 2025-04-17 | 86.91 |
| 2025-04-16 | 88.54 |
| 2025-04-15 | 88.54 |
| 2025-04-14 | 89.63 |
| 2025-04-11 | 87.09 |
| 2025-04-10 | 89.45 |
| 2025-04-09 | 89.99 |
| 2025-04-08 | 89.27 |
| 2025-04-07 | 87.82 |
| 2025-04-04 | 89.81 |
| 2025-04-03 | 94.52 |
| 2025-04-02 | 95.06 |
| 2025-04-01 | 96.51 |
| 2025-03-31 | 94.70 |
| 2025-03-28 | 97.60 |
| 2025-03-27 | 99.23 |
| 2025-03-26 | 99.23 |
| 2025-03-25 | 101.04 |
| 2025-03-24 | 101.22 |
| 2025-03-21 | 96.88 |
| 2025-03-20 | 96.15 |
| 2025-03-19 | 95.97 |
| 2025-03-18 | 98.33 |